Alchemab Therapeutics is focused on leveraging the power of adaptive immunity to develop next-generation antibody therapeutics aimed at treating challenging diseases. Their innovative approach involves identifying resilient individuals, such as long-term cancer survivors, to understand how they overcome or resist diseases. By mining the antibody receptors of these individuals, Alchemab can discover naturally occurring protective antibodies. This process begins with the identification of resilient populations, followed by the sequencing of their B cells to generate extensive antibody repertoires. These sequences are then analyzed using advanced computational tools to identify functionally related protective antibodies that are common among the resilient individuals.

Once potential therapeutic antibodies are identified, Alchemab conducts further research to discover their binding targets and understand their protective properties. The selected convergent antibodies undergo a series of assays to elucidate their mechanisms of action and optimize them for therapeutic use. This comprehensive approach allows Alchemab to develop potent therapeutic candidates that aim to replicate the protective effects observed in resilient individuals, ultimately providing new treatment options for patients suffering from hard-to-treat diseases, including neurodegenerative disorders and various cancers.

United Kingdom

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Alchemab Therapeutics

Company Details